Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

NCT05502315 is registered in ClinicalTrials.gov with Rana McKay, MD as lead sponsor.

NCT NCT05502315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05502315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Lead sponsor
Rana McKay, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 2, 2023
Completion date
October 12, 2027
Enrollment
47 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, metastatic cancer